Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial by Saltzman, Adam J. et al.
a
9
v
(
b
C
w
h
2
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 4 , N O . 9 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 1 . 0 6 . 0 1 2Long-Term Impact of Chronic Kidney Disease in
Patients With ST-Segment Elevation Myocardial
Infarction Treated With Primary Percutaneous
Coronary Intervention
The HORIZONS-AMI (Harmonizing Outcomes With Revascularization
and Stents in Acute Myocardial Infarction) Trial
Adam J. Saltzman, MD,* Gregg W. Stone, MD,* Bimmer E. Claessen, MD,*
Amar Narula, MD,* Selene Leon-Reyes, PHD,* Giora Weisz, MD,* Bruce Brodie, MD,‡
Bernhard Witzenbichler, MD,§ Giulio Guagliumi, MD, Ran Kornowski, MD,¶
Dariusz Dudek, MD,# D. Christopher Metzger, MD,** Alexandra J. Lansky, MD,*
Eugenia Nikolsky, MD, PHD,* George D. Dangas, MD, PHD,† Roxana Mehran, MD*†
New York, New York; Greensboro, North Carolina; Berlin, Germany; Bergamo, Italy;
Petach Tikva, Israel; Krakow, Poland; and Kingsport, Tennessee
Objectives This study sought to investigate the impact of chronic kidney disease (CKD) in patients
undergoing percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction
(STEMI) with different antithrombotic strategies.
Background CKD is associated with increased risk of adverse ischemic and hemorrhagic events af-
ter primary PCI for STEMI.
Methods HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myo-
cardial Infarction) trial was a multicenter, international, randomized trial comparing bivalirudin
monotherapy or heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) during primary PCI in STEMI. CKD,
deﬁned as creatinine clearance 60 ml/min, was present at baseline in 554 of 3,397 patients
(16.3%). Patients were followed for 3 years. Net adverse cardiac event (NACE) was deﬁned as the
composite of death, reinfarction, ischemia-driven target vessel revascularization (TVR), stroke or non–
coronary artery bypass grafting (CABG)-related major bleeding.
Results Patients with CKD compared with patients without had higher rates of NACE (41.4% vs. 23.8%,
p  0.0001), death (18.7% vs. 4.4%, p  0.0001), and major bleeding (19.3% vs. 6.7%, p  0.0001). Multivari-
ble analysis identiﬁed baseline creatinine as an independent predictor of death at 3 years (hazard ratio: 1.51,
5% conﬁdence interval: 1.21 to 1.87, p  0.001). Patients with CKD randomized to bivalirudin monotherapy
ersus heparin plus GPI had no signiﬁcant difference in major bleeding (19.0% vs. 19.6%, p  0.72) or death
19.0% vs. 18.4%, p  0.88) at 3 years. In patients with CKD, there was no difference in the rates of TVR in
are-metal stents (BMS) versus drug-eluting stents (DES) at 3 years (14.1% vs. 15.1%, p  0.8).
onclusions STEMI patients with CKD have signiﬁcantly higher rates of death and major bleeding compared
ith those without CKD. In patients with CKD, there appears to be no beneﬁt of bivalirudin compared with
eparin  GPI, or DES versus BMS during primary PCI in improving clinical outcomes. (J Am Coll Cardiol Intv
011;4:1011–9) © 2011 by the American College of Cardiology Foundation
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1012Chronic kidney disease (CKD) is associated with reduced survival
and increased bleeding in patients undergoing percutaneous cor-
onary intervention (PCI) and coronary artery bypass grafting
(CABG) for a variety of indications, including ST-segment
elevation myocardial infarction (STEMI) (1–13). Substantial re-
search has focused on identifying optimal antithrombotic agents in
this patient population to maximize clinical benefit while mini-
mizing bleeding complications (14). Previous work has suggested
hat patients with CKD have increased levels of oxidative stress,
ccelerated atherosclerosis, increased levels of thrombin, and sub-
ptimal use of guideline-recommended therapies (15). Earlier
data have demonstrated that bivalirudin, a direct thrombin inhib-
itor, may be associated with better outcomes in patients with
CKD (8,16–18). In a previous
analysis of CKD patients with non–
ST-segment elevation acute coro-
nary syndromes, treatment with bi-
valirudin was demonstrated to have
similar ischemic outcomes, but sig-
nificantly less 30-day major bleed-
ing than unfractionated heparin
(UFH) or enoxaparin plus glyco-
protein IIb/IIIa inhibitors (GPIs)
(13).
The HORIZONS-AMI (Har-
monizing Outcomes With Re-
vascularization and Stents in
Acute Myocardial Infarction)
trial demonstrated that in pa-
tients with STEMI, bivalirudin
compared with UFH plus a GPI
was associated with lower rates
of major bleeding, cardiac mor-
tality, and all-cause mortality at
30 days and 1 year (19,20). In
this substudy of HORIZONS-
AMI, we examined the relation-
ship between CKD and clinical
outcomes with follow-up through
3 years. Moreover, we investigated
the relative safety and efficacy of
an antithrombotic regimen consisting of bivalirudin mono-
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Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CI  confidence interval
CKD  chronic kidney
disease
CrCl  creatinine clearance
DES  drug-eluting stent(s)
GPI  glycoprotein IIb/IIIa
inhibitor
HR  hazard ratio
MACE  major adverse
cardiovascular event(s)
NACE  net adverse cardiac
event(s)
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TVR  target vessel
revascularization
UFH  unfractionated heparinCordis, Cook, Eli Lilly, EuroCor, Glaxo, Invatec, Medtronic, The Medicines Co.,
MSD, Nycomed, Orbus-Neich, Pfizer, Possis, Promed, Sanofi-Aventis, Siemens, atherapy compared with UFH plus a GPI in patients with and
without CKD.
Methods
Patient population, randomization, and study protocol. The
design, inclusion and exclusion criteria, and results of the
HORIZONS-AMI trial have been previously published
(19–21). Briefly, HORIZONS-AMI was a prospective,
open-label, multicenter trial involving patients with STEMI
who were undergoing primary PCI as a management
strategy. A total of 3,602 patients with STEMI presenting
within 12 h of symptom onset were prospectively random-
ized to UFH plus the routine use of a GPI versus bivalirudin
plus provisional use of a GPI reserved for predefined
refractory thrombotic complications. Immediate coronary
angiography with left ventriculography was performed after
randomization, followed by PCI, CABG, or medical man-
agement at the discretion of the physician. In a second
randomization, 3,006 eligible patients were randomly as-
signed to either a Taxus Express paclitaxel-eluting stent
(Boston Scientific, Natick, Massachusetts) or to an other-
wise identical Express bare-metal stent (BMS) (Boston
Scientific).
UFH was administered as an intravenous bolus of 60
IU/kg, and then continued boluses were administered to
reach a target activated clotting time of 200 to 250 s. GPIs
were administered before PCI in all patients in the control
group; either abciximab (a bolus of 0.25 mg/kg followed by
an infusion of 0.125 g/kg/min; maximum dose, 10 g/min) or
ouble-bolus eptifibatide (a bolus of 180 g/kg followed by
an infusion of 2.0 g/kg/min, with a second bolus given 10
in after the first) was permitted at the discretion of the
nvestigator and was continued for 12 h (abciximab) or 12 to
8 h (eptifibatide). In patients with a creatinine clearance
CrCl) 50 ml/min, the infusion dose of eptifibatide was
educed to 1.0 g/kg/min. Bivalirudin was administered as
an intravenous bolus of 0.75 mg/kg, followed by an infusion
of 1.75 mg/kg/h. For patients with a CrCl30 ml/min, the
infusion rate was decreased to 1 mg/kg/h. For those patients
on hemodialysis, the infusion rate was decreased to 0.25
mg/kg/h. Both heparin and bivalirudin were discontinued at
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1013the completion of angiography or PCI unless clinically
indicated thereafter.
Aspirin (324 mg given orally or 500 mg administered
intravenously) was given in the emergency room, after
which 300 to 325 mg was given orally every day during the
hospitalization and 75 to 81 mg every day thereafter
indefinitely. A loading dose of clopidogrel (either 300 mg or
600 mg, at the discretion of the investigator), or ticlopidine
(500 mg), in case of allergy to clopidogrel, was administered
before catheterization, followed by 75 mg orally every day
for at least 6 months (1 year or longer recommended).
The study was approved by the institutional review board
or ethics committee at each participating center, and all
patients signed written, informed consent.
Study endpoints and deﬁnitions. The HORIZONS-AMI
rial was powered for two 30-day endpoints: major bleeding
not related to CABG) and combined net adverse clinical
vents (NACE, consisting of non–CABG-related major
leeding or a composite of major adverse cardiovascular
vents (MACE), including death, reinfarction, target vessel
evascularization for ischemia, or stroke). Non–CABG-
elated major bleeding was defined as intracranial or intra-
cular hemorrhage, a 5-cm or greater hematoma at the
ccess site, or bleeding requiring intervention, a decrease in
he hemoglobin level 4 g/dl without an overt bleeding
ource or3 g/dl with an overt bleeding source, reoperation
or bleeding, or blood transfusion. Outcomes for the pri-
ary endpoints were assessed out to 3 years. All events were
djudicated by an independent clinical events committee
linded to treatment assignment.
CKD was defined as a calculated CrCl of 60 ml/min
sing the Cockcroft-Gault equation based on admission
aboratory analysis (before any contrast media exposure)
22). Anemia was defined using the World Health Orga-
Figure 1. Patient Distribution in the HORIZONS-AMI Trial
Patient distribution in the HORIZONS-AMI trial according to the availability
of baseline creatinine clearance data and randomization. CrCl  creatinine
clearance; STEMI  ST-segment elevation myocardial infarction.ization criteria (hemoglobin 13 g/dl for men and 12
g/dl for women) (23). The present analysis examined the
baseline features and 30-day, 1-year, and 3-year outcomes in
patients with CKD (CrCl 60 ml/min) and severe CKD
(CrCl 30 ml/min) versus those without, and patients
randomized to bivalirudin versus UFH plus a GPI accord-
ing to the presence or absence of CKD.
Statistical analysis. All analyses are by intention to treat.
Chi-square tests were used to compare categorical vari-
ables. Continuous variables are presented as medians
with interquartile ranges, and were compared using the
Wilcoxon rank sum test. Follow-up analysis was per-
formed using time-to-event data (for which patients were
censored at the time of withdrawal from the study or at
last follow-up), with the event rates estimated by Kaplan-
Table 1. Baseline Characteristics, Procedures, and Discharge
Medications According to Renal Function
CrCl >60 ml/min
(n  2,783)
CrCl <60 ml/min
(n  554) p Value
Age, yrs 57.9 [50.8–65.5] 75.4 [70.4–80.3] 0.0001
Male 81.1% 55.2% 0.0001
BMI, kg/m2 27.5 [25.0–30.7] 24.8 [22.7–27.3] 0.0001
Diabetes 16.0% 19.3% 0.05
Hypertension 49.9% 69.1% 0.0001
Hyperlipidemia 42.2% 46.2% 0.08
Current smoking 50.4% 24.4% 0.0001
Family history of CAD 31.7% 19.0% 0.0001
Prior myocardial infarction 9.7% 15.3% 0.0001
Prior percutaneous coronary
intervention
9.8% 13.9% 0.003
Prior CABG 2.3% 5.6% 0.0001
Killip class 1 7.3% 13.9% 0.0001
Anemia 8.2% 23.7% 0.0001
Peripheral artery disease 3.5% 9.2% 0.0001
History of congestive heart
failure
5.1% 2.6% 0.001
Primary management strategy
PCI 92.2% 93.2% 0.43
DES 75.0% 75.5% 0.83
BMS 25.0% 24.5% 0.83
CABG 1.6% 1.8% 0.78
Medical therapy 6.1% 4.9% 0.22
Discharge medications
Aspirin 96.9% 97.7% 0.28
Thienopyridine 91.2% 91.6% 0.72
ACEI or ARB 81.9% 75.4% 0.0001
Beta-blocker 90.3% 80.0% 0.0001
Statin 93.2% 87.9% 0.0001
Values are median [interquartile range] or %.
ACEi angiotensin converting enzyme inhibitors; ARB angiotensin receptor blocker; BMI
body mass index; BMS  bare-metal stent(s); CABG  coronary artery bypass grafting; CAD 
coronary artery disease; CrCl creatinine clearance; DES drug-eluting stent(s); PCI percuta-
neous coronary intervention.Meier methods, and were compared with the log-rank
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1014test. Cox multivariable regression models were used to
identify independent predictors of NACE, death,
MACE, and major bleeding. The model included age,
diabetes, recent smoking, hypertension, hyperlipidemia,
prior myocardial infarction (MI), prior PCI, prior
CABG, congestive heart failure (CHF), peripheral vessel
disease, end-stage renal disease on current dialysis, major
cardiac rhythm/rate disturbance, gender, Killip class 2 to
4 (vs. class 1), baseline Thrombolysis In Myocardial
Infarction score 0 to 1 (vs. 2 to 3), creatinine level, left
ventricular ejection fraction (10% decrease), platelet
count (per 100,000 increase), current smoker, baseline
hemoglobin (10-U decrease), mitral regurgitation 3 to
4 (vs. 1 to 2), left anterior descending disease, and
andomization arm (bivalirudin monotherapy vs. UFH
lus a GPI). The final Cox models used were selected by
he use of a stepwise selection algorithm, with an entry
nd exit level of significance of 0.10. Interaction tests
ere performed using multivariable Cox models with
ain effects of CKD and randomization arm plus the
Figure 2. Time-to-Event Curves Stratified by the Presence or Absence of C
Time-to-event curves stratiﬁed by the presence or absence of chronic kidney d
coronary artery bypass grafting (CABG) major bleeding; and (D) major adverse
hazard ratio.interaction only. All statistical analyses were performed
by SAS version 9.2 (SAS Institute Inc., Cary, North
Carolina).
Results
Of the 3,602 randomized patients, 3,397 patients had
available baseline creatinine clearance data, 554 of whom
(16.3%) had CKD (Fig. 1). Compared with those without
CKD, patients with CKD were more likely to be older,
female, diabetic, anemic, or hypertensive, to have had prior
MI, and to have undergone prior PCI or CABG (Table 1).
Patients with CKD were more likely to have peripheral
artery disease, and more often had Killip class 1 at the
time of presentation compared with those without CKD.
There was no difference in the primary management strat-
egy (PCI, CABG, medical) or in the type of stent used
between those with and without CKD. CKD patients were
less likely to receive an angiotensin-converting enzyme
inhibitor or angiotensin receptor blocker, statin, or beta-
(CKD) for (A) net adverse cardiac events; (B) all-cause mortality; (C) non-
ovascular events. CI  conﬁdence interval; CrCl  creatinine clearance; HR KD
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1015blocker at discharge. There were no significant differences in
patients with and without CKD in the discharge rates of
aspirin (96.9% vs. 97.7%, p  0.28) or clopidogrel (91.2%
vs. 91.6%, p  0.73) use. Patients with (n  3,337)
compared with patients without (n 265) available baseline
creatinine data had no significant differences in NACE
(26.7% vs. 25.0%, p  0.6), death (6.8% vs. 7.6%, p  0.6),
or major bleeding (8.7% vs. 8.2%, p  0.8).
Renal function and clinical outcomes. Patients with com-
ared with those without CKD had increased rates of
ACE at 30 days (21.3% vs. 9.0%, p  0.0001), 1 year
30.3% vs. 14.4%, p  0.0001), and 3 years (41.4% vs.
3.8%, p  0.0001), with the hazard curves diverging over
ime (Fig. 2A). At 3 years, patients with compared with
Table 2. Event Rates in Patients With and Without C
CrCl >60 ml/
(n  2,783
30-day outcomes
NACE 9.1% (252)
MACE 4.3% (120)
Death 1.4% (40)
Cardiac death 1.3% (37)
Reinfarction 1.8% (50)
Death or reinfarction 3.0% (84)
Stroke 0.5% (15)
Ischemic TVR 2.3% (63)
Major bleeding (non–CABG-related) 5.7% (159)
Deﬁnite or probable stent thrombosis 2.3% (58)
1-yr outcomes
NACE 14.3% (393)
MACE 10.1% (276)
Death 2.5% (68)
Cardiac death 1.8% (49)
Reinfarction 3.6% (97)
Death or reinfarction 5.7% (157)
Stroke 0.9% (25)
Ischemic TVR 6.6% (177)
Major bleeding (non–CABG-related) 6.0% (165)
Deﬁnite or probable stent thrombosis 3.2% (80)
3-yr outcomes
NACE 23.8% (640)
MACE 19.8% (528)
Death 4.4% (117)
Cardiac death 2.7% (72)
Reinfarction 6.8% (179)
Death or reinfarction 10.5% (281)
Stroke 1.6% (42)
Ischemic TVR 13.1% (344)
Major bleeding (non–CABG-related) 6.7% (184)
Deﬁnite or probable stent thrombosis 4.9% (119)
Values are % (N). All p values are comparing CrCl 60 ml/min to CrCl
CKD chronic kidney disease;MACEmajor adverse cardiac eventvessel revascularization; other abbreviations as in Table 1.hose without CKD had higher rates of death (18.7% vs.
.4%, p  0.0001) (Fig. 2B), major bleeding (non–CABG-
elated) (19.3% vs. 6.7%, p  0.0001) (Fig. 2C), stroke
3.2% vs. 1.6%, p  0.01), and MACE (16.0% vs. 11.1%,
 0.003) (Fig. 2D). At 3 years, 52.9% of patients
resenting with STEMI and more advanced CKD (CrCl
30 ml/min) were deceased (Table 2). Multivariate analysis
onfirmed admission creatinine as an independent predictor
f risk for death (hazard ratio [HR]: 1.51, 95% confidence
nterval [CI]: 1.21 to 1.87, p  0.001), NACE (HR: 1.39,
5% CI: 1.24 to 1.56, p 0.0001), MACE (HR: 1.38, 95%
I: 1.20 to 1.59, p  0.0001), and non-CABG major
leeding (HR: 1.43, 95% CI: 1.26 to 1.62, p  0.0001) at
years (Table 3).
CrCl 30–60 ml/min
(n  506)
CrCl <30 ml/min
(n  48) p Value
18.4% (93) 62.5% (30) 0.0001
9.9% (50) 29.2% (14) 0.0001
6.7% (34) 23.0% (11) 0.0001
6.0% (30) 19.1% (9) 0.0001
2.0% (10) 4.9% (2) 0.38
8.1% (41) 27.1% (13) 0.0001
1.6% (8) 2.3% (1) 0.01
2.6% (13) 2.4% (1) 0.9
12.1% (60) 45.2% (20) 0.0001
2.4% (10) 11.1% (4) 0.003
27.2% (136) 74.4% (35) 0.0001
18.5% (92) 49.3% (23) 0.0001
9.8% (49) 36.5% (17) 0.0001
7.2% (36) 23.6% (11) 0.0001
5.4% (25) 13.9% (5) 0.001
13.8% (69) 45.2% (21) 0.0001
2.3% (11) 2.3% (1) 0.02
7.7% (36) 9.3% (3) 0.6
14.3% (70) 45.2% (20) 0.0001
2.9% (12) 11.1% (4) 0.01
37.9% (187) 79.5% (37) 0.0001
30.0% (147) 70.0% (32) 0.0001
15.5% (76) 52.9% (24) 0.0001
8.6% (42) 26.8% (12) 0.0001
7.5% (34) 26.1% (8) 0.0001
21.3% (104) 61.8% (28) 0.0001
3.2% (15) 2.3% (1) 0.04
13.6% (61) 25.3% (7) 0.3
16.9% (81) 45.2% (20) 0.0001
4.2% (17) 19.7% (6) 0.0001
ml/min.
yocardial infarction; NACE net adverse clinical events; TVR targetKD
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1016There was no difference between those with versus
without CKD in the type of stent received (Taxus drug-
eluting stent [DES], 75.0% vs. 75.5%, p  0.83; Express
BMS 25.0% vs. 24.5%, p  0.83). In patients without
KD, the rate of MACE at 3 years was significantly higher
n those receiving BMS compared with DES (22.7% vs.
8.1%, p  0.01) primarily driven by increased rates of
arget vessel revascularization (TVR) in the BMS group
18.2% vs. 13.2%, p  0.003). However, in patients with
CKD, there was no difference in the 3-year MACE rates in
those receiving BMS versus DES (33.3% vs. 33.6%, p 
0.9), and there was no difference in rates of TVR in BMS
versus DES at 3 years (14.1% vs. 15.1%, p  0.8). The test
for interaction of CKD and stent type used on 3-year
outcomes showed no significance for death, MACE,
NACE, stent thrombosis, or TVR (Table 4).
Impact of antithrombotic regimen in patients with CKD.
Baseline demographic, clinical, and procedural characteris-
tics were similar among patients with CKD in the
Table 3. Independent Predictors of Adverse Clinical Events and
Major Bleeding Not Related to Bypass Surgery at 3-Years Follow-Up
HR (95% CI) p Value
Predictors of NACE
Creatinine 1.39 (1.24–1.56) 0.0001
Killip class 1 1.32 (1.04–1.78) 0.04
Admission hemoglobin 3.10 (2.03–6.11) 0.0001
Prior PCI 1.47 (1.15–1.88) 0.002
LAD culprit lesion 1.25 (1.05–1.54) 0.03
Ejection fraction 1.14 (1.07–1.54) 0.0001
Insulin treated diabetes 1.53 (1.18–2.25) 0.01
Predictors of death
Creatinine 1.51 (1.21–1.87) 0.001
Age 2.08 (1.72–2.52) 0.0001
Killip class 1 1.89 (1.20–2.98) 0.006
Admission hemoglobin 6.35 (1.94–20.79) 0.002
Prior tobacco use 1.67 (1.12–2.48) 0.01
Predictors of MACE
Creatinine 1.38 (1.20–1.59) 0.0001
Admission hemoglobin 2.94 (1.58–5.45) 0.001
Prior PCI 1.65 (1.27–2.14) 0.001
LAD culprit lesion 1.43 (1.15–1.78) 0.001
Ejection fraction 1.17 (1.09–1.25) 0.001
Prior tobacco use 1.34 (1.09–1.65) 0.006
Predictors of non–CABG major bleeding
Creatinine 1.43 (1.26–1.62) 0.0001
Age 1.35 (1.21–1.49) 0.0001
Male (vs. female) 0.57 (0.45–0.73) 0.001
Bivalirudin randomization 0.67 (0.53–0.85) 0.001
Values are admission creatinine, hemoglobin per 10-U decrease, ejection fraction per 10-U
decrease, age per 10-year increase.
CI  confidence interval; HR  hazard ratio; LAD  left anterior descending coronary artery;
other abbreviations as in Tables 1 and 2.2 antithrombotic treatment groups. However, peak acti- cvated clotting time values were higher (381 s vs. 272 s, p 
0.0001), and rates of use of angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers at discharge were
lower (69.3% vs. 78.9%, p  0.0132) in the bivalirudin
group compared with the UFH plus GPI group. Among
patients with CKD treated with bivalirudin versus UFH 
GPI, there were no significant differences in NACE and
death at 30 days or 3 years (Table 5). In contrast, in patients
without CKD, patients treated with bivalirudin had lower
30-day rates of NACE (7.3% vs. 10.7%, p  0.002), driven
by significantly reduced rates of mortality and major bleed-
ing. In patients without CKD, the difference in NACE at 1
year (13.2% vs. 15.4%, p  0.08) and 3 years was no longer
significant. However, bivalirudin monotherapy resulted in
significantly less non–CABG-related major bleeding at 3
years compared with heparin plus a GPI (5.0% vs. 8.5%,
p  0.0003), and reduced mortality (3.4% vs. 5.4%, p 
0.01). The interaction between CKD and antithrombotic
strategy was significant for death at 30 days (p  0.02), and
approached statistical significance for death (p  0.07) and
major bleeding (p  0.06) at 3 years (Table 5).
Discussion
In the present analysis from the HORIZONS-AMI study,
the presence of CKD in patients with STEMI undergoing
PCI was a powerful predictor of adverse clinical events at 3
years. Patients with CKD had higher 3-year rates of death,
stroke, non–CABG-related major bleeding, and the com-
posite outcomes of MACE and NACE. High-risk patients
with CKD did not experience lower rates of NACE with
bivalirudin monotherapy compared with UFH and a GPI.
In addition, the long-term benefit of DES on TVR appears
to be diminished in patients with CKD.
In multivariable analysis, admission creatinine was an
independent predictor for death, MACE, NACE, and
major bleeding at 3 years. Indeed, CKD conferred greater
risk for NACE then traditional STEMI risk factors such as
a reduced ejection fraction, left anterior descending coro-
nary artery culprit vessel, or a high Killip class. Interestingly,
low-admission hemoglobin conferred the greatest risk (HR:
3.10, CI: 2.03 to 6.11, p 0.0001) for NACE at 3 years. In
addition, patients with the lowest CrCl (30 ml/min) expe-
ienced a relative increase in clinical events compared with
atients with moderate CrCl 30 to 60 ml/min reduction. The
isk of dying within 3 years if one presents with a CrCl 30
l/min and a STEMI exceeds most major cancers.
Consistent with previous reports, CKD was associated
ith higher rates of adverse clinical events in the current
tudy (24,25). Compared with patients without CKD,
atients with CKD have more cardiac risk factors and
omorbid conditions. Moreover, patients with CKD re-
eived fewer evidence-based strategies to modify cardiovas-
ular risk compared with patients without CKD (7,26).
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1017Notably, the predominant driver for the higher rates of
NACE in CKD patients over 3 years were death, stroke,
and major bleeding, not reinfarction or repeat revascular-
Table 4. Outcomes According to Baseline Renal Function and Stent Type
CrCl <60 ml/min
Taxus
(n  262)
BMS
(n  292) H
30-day outcomes
NACE 21.4% (56) 23.0% (67) 0.
MACE 12.6% (33) 10.6% (31) 1.
Death 8.4% (22) 7.9% (23) 1.
MI 3.2% (8) 1.4% (4) 2.
Stroke 2.0% (5) 1.4% (4) 1.
Ischemic TVR 2.0% (5) 3.2% (9) 0.
Major bleeding (non–CABG-related) 12.7% (32) 16.7% (48) 0.
Deﬁnite or probable stent thrombosis 2.8% (6) 3.2% (8) 0.
3-yr outcomes
NACE 41.1% (105) 41.7% (119) 0.
MACE 33.6% (85) 33.3% (94) 1.
Death 19.0% (48) 18.4% (52) 1.
MI 7.3% (17) 9.9% (25) 0.
Stroke 2.4% (6) 3.9% (10) 0.
Ischemic TVR 14.7% (33) 13.7% (35) 1.
Major bleeding (non–CABG-related) 19.0% (46) 19.6% (55) 0.
Deﬁnite or probable stent thrombosis 5.0% (10) 5.6% (13) 0.
Values are % (N) unless otherwise indicated.
Abbreviations as in Tables 1, 2, and 3.
Table 5. Outcomes According to Baseline Renal Function and Randomized
CrCl <60 ml/min
Bivalirudin
(n  262)
Heparin  GPI
(n  292)
30-day outcomes
NACE 21.1% (55) 21.6% (63) 0
MACE 12.7% (33) 10.6% (31) 1
Death 8.4% (22) 7.9% (23) 1
MI 3.2% (8) 1.4% (4) 2
Stroke 2.0% (5) 1.4% (4) 1
Ischemic TVR 2.0% (5) 3.2% (9) 0
Major bleeding (non–CABG-related) 12.3% (31) 15.3% (44) 0
Deﬁnite or probable stent thrombosis 2.8% (6) 3.2% (8) 0
3-yr outcomes
NACE 41.1% (105) 41.7% (119) 0
MACE 33.6% (85) 33.3% (94) 1
Death 19.0% (48) 18.4% (52) 1
MI 7.3% (17) 9.9% (25) 0
Stroke 2.4% (6) 3.9% (10) 0
Ischemic TVR 14.7% (33) 13.7% (35) 1
Major bleeding (non–CABG-related) 19.0% (46) 19.6% (55) 0
Deﬁnite or probable stent thrombosis 5.0% (10) 5.6% (13) 0
Values are % (N) unless otherwise indicated.Abbreviations as in Tables 1, 2, and 3.ization. The 3-fold increase in bleeding in the current study
is consistent with a previous report highlighting the impact
of CKD on bleeding complications (13), and may be
CrCl >60 ml/min
p Value for
Interaction% CI)
Taxus
(n  1,775)
BMS
(n  591) HR (95% CI)
6–1.34) 8.3% (148) 9.0% (53) 0.92 (0.67–1.26) 0.14
5–1.99) 4.0% (71) 3.7% (22) 1.07 (0.67–1.73) 0.84
1–1.95) 1.2% (22) 1.2% (7) 1.05 (0.45–2.45) 0.88
9–7.61) 1.7% (30) 1.7% (10) 1.00 (0.49–2.05) 0.24
9–5.35) 0.3% (6) 0.5% (3) 0.66 (0.17–2.65) 0.77
1–1.88) 2.5% (44) 2.4% (14) 1.05 (0.57–1.91) 0.68
8–1.17) 5.3% (94) 6.1% (36) 0.86 (0.59–1.26) 0.06
0–2.53) 2.5% (43) 2.4% (14) 1.03 (0.56–1.88) 0.31
5–1.26) 21.8% (380) 26.9% (156) 0.78 (0.65–0.95) 0.14
6–1.36) 18.1% (315) 22.7% (131) 0.77 (0.63–0.95) 0.50
0–1.53) 4.0% (69) 4.2% (24) 0.95 (0.60–1.51) 0.56
1–1.40) 6.7% (115) 6.0% (34) 1.12 (0.77–1.65) 0.54
5–1.86) 1.3% (22) 1.4% (8) 0.91 (0.40–2.04) 0.70
5–1.68) 12.3% (210) 17.8% (101) 0.67 (0.53–0.85) 0.66
3–1.38) 6.1% (107) 7.2% (42) 0.84 (0.59–1.20) 0.04
9–2.04) 5.3% (90) 4.2% (24) 1.25 (0.80–1.96) 0.87
hrombotic Regimen
CrCl >60 ml/min
p Value for
Interaction% CI)
Bivalirudin
(n  1399)
Heparin  GPI
(n  1384) HR (95% CI)
8–1.41) 7.3% (102) 10.7% (148) 0.67 (0.52–0.87) 0.16
5–1.99) 4.2% (58) 4.5% (62) 0.93 (0.65–1.33) 0.39
1–1.95) 0.8% (11) 2.1% (29) 0.37 (0.19–0.75) 0.02
9–7.62) 1.7% (24) 1.9% (26) 0.91 (0.52–1.59) 0.17
9–5.35) 0.6% (9) 0.4% (6) 1.48 (0.53–4.16) 0.97
1–1.89) 2.7% (37) 1.7% (24) 1.53 (0.92–2.56) 0.12
0–1.25) 4.0% (55) 7.4% (102) 0.52 (0.38–0.72) 0.26
1–2.54) 2.8% (35) 2.0% (24) 1.43 (0.85–2.40) 0.37
5–1.26) 23.1% (312) 24.4% (328) 0.92 (0.79–1.07) 0.74
6–1.36) 20.2% (271) 19.4% (257) 1.04 (0.88–1.24) 0.85
0–1.53) 3.4% (46) 5.4% (71) 0.63 (0.43–0.91) 0.07
1–1.40) 6.1% (81) 7.6% (98) 0.80 (0.60–1.08) 0.86
5–1.86) 1.6% (21) 1.6% (21) 0.97 (0.53–1.78) 0.53
5–1.68) 14.4% (192) 11.8% (152) 1.25 (1.01–1.55) 0.49
3–1.38) 5.0% (69) 8.5% (115) 0.58 (0.43–0.78) 0.06
9–2.04) 4.9% (61) 4.9% (58) 1.02 (0.71–1.46) 0.76R (95
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1018attributed to functional abnormalities in platelets and coag-
ulation factors in patients with CKD (27,28).
In the HORIZONS-AMI trial, among 3,602 patients
with STEMI undergoing primary PCI randomized to
bivalirudin monotherapy versus heparin  GPI, bivalirudin
esulted in reduced rates of major bleeding, cardiac mortal-
ty, and all-cause mortality. Somewhat surprisingly, these
enefits were restricted largely to patients without CKD. In
ontrast, a meta-analysis of 3 randomized trials comparing
ivalirudin with UFH during PCI showed a significant
eduction in bleeding events with bivalirudin in patients
ith an estimated glomerular filtration rate of 30 to 59
l/min (8). Moreover, a subgroup analysis of 886 patients
ith CKD in the REPLACE-2 (Second Randomized
valuation in PCI Linking Bivalirudin to Reduced Clinical
vents) trial reported fewer major bleeding complications
3.2% vs. 7.1%, p  0.01) and no significant difference in
0-day rates of a composite ischemic endpoint (5.1% vs. 7.1%,
 0.21) with bivalirudin compared with UFH plus a GPI
16). Finally, a recent analysis from the ACUITY (Acute
atheterization and Urgent Intervention Triage strategY) trial
eported significantly lower rates of 30-day major bleeding
ith bivalirudin monotherapy compared with UFH plus a GPI
n 2,469 patients with non–ST-segment elevation acute cor-
nary syndromes and CKD (13). The interaction p values in
he present study are of borderline significance, and with
nly 554 STEMI patients with CKD, we cannot exclude
he possibility that chance may explain the differences
etween the present and prior bivalirudin trials in patients
ith CKD (20,29,30).
Although CKD was a pre-specified subgroup for analysis,
he HORIZONS-AMI trial was not powered for formal
uperiority or noninferiority testing of this subgroup, and
he results should be considered hypothesis generating.
urthermore, 7.4% of patients randomized in the
ORIZONS-AMI trial did not have baseline creatinine
alues and were excluded from the present analysis.
onclusions
In STEMI patients treated with primary PCI, CKD was
associated with increased long-term rates of NACE, bleed-
ing, and death. There appears to be no benefit of bivalirudin
compared with heparin  GPI during PCI in reducing
major bleeding and mortality in patients with CKD. In
addition, there appears to be no benefit for DES on future
TVR in patients with CKD. Further investigation is war-
ranted to identify novel therapeutic strategies to improve the
untoward prognosis of patients with CKD and STEMI.
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